TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17698804
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential chemotherapy with PBSC support (two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support, HD melphalan added to the final cycle)
Study: 17698804
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination chemotherapy
Study: 17698804
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential chemotherapy with PBSC support
Study: 26580093
Drug: Investigational vaccine
Normalized name: INVESTIGATIONAL VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational vaccine (Shan5™)
Study: 23549123
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml ropivacaine 7.5 mg/ml
Study: 23549123
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 0.9% saline
Study: 17570651
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day with low-calorie diet
Study: 26050853
Drug: Tualang honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tualang honey + antibiotic
Study: 2203467
Drug: Antibiotic only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic only
Study: 21209031
Drug: Antiandrogenic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogenic oral contraceptive
Study: 10500311
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (20 mg IV bolus followed by 60 mg infusion over 1 hour)
Study: 10500311
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus (80 mg)
Study: 10500311
Drug: Split bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split bolus (2 x 40 mg at 30-minute intervals)
Study: 1785240
Drug: Aminophylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (3 mg.kg‐1)
Study: 19150139
Drug: Codeine/acetaminophen (C/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/acetaminophen (C/A)
Study: 14569512
Drug: Clinical response
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical response evaluation after 2 cycles of chemotherapy
Study: 10533734
Drug: Intrasphincteric injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasphincteric injection of botulinum toxin A (20 U injected into each of the four quadrants in the lower esophageal sphincter)
Study: 30012909
Drug: Double-level Retrolaminar
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-level Retrolaminar Paravertebral Block (RLB) with 15 ml ropivacaine (0.5%) for each lamina of T2 and T4 vertebrae
Study: 633779
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g cephradine with 40 mg furosemide t.i.d. peroral
Study: 633779
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g cephalothin
Study: 20804454
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily (n = 59)
Study: 16419643
Drug: 185 mg
Normalized name: amdinocillin 185 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 185 mg GCE once a day
Study: 12640589
Drug: Quetiapine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine at a mean dose of 24.9 mg/d
Study: 22450386
Drug: hT(2)W‐3D‐FLAIR obtained
Approvals — FDA: no, EMA: no, PMDA: no
Description: hT(2)W‐3D‐FLAIR obtained 10 min, 3.5 hours, and 4 hours after GBCM administration in Group A
Study: 22450386
Drug: hT(2)W‐3D‐FLAIR obtained
Approvals — FDA: no, EMA: no, PMDA: no
Description: hT(2)W‐3D‐FLAIR obtained before and 10 min, 4 hours, and 4.5 hours after GBCM administration in Group B
Study: 18797646
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention and contact (BIC) plus treatment as usual
Study: 11262469
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered iron sucrose plus recombinant human erythropoietin
Study: 9525542
Drug: Warfarin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin anticoagulation
Study: 3443154
Drug: Fenoterol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 1.25 mg
Study: 7125306
Drug: Fenoterol 2.5
Normalized name: fenoterol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 2.5 mg
Study: 31261570
Drug: YIC therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: YIC therapeutic vaccine
Study: 23602291
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IV omega-3 polyunsaturated fatty acids (PUFAs)
Study: 19008718
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg for 3 months
Study: 19008718
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg for 3 months
Study: 11081989
Drug: Pycnogenol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (100 mg 2-3 times/day for 2 months)
Study: 9322471
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus of clonidine 150 micrograms plus morphine 2 mg
Study: 9322471
Drug: Epidural patient-controlled
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% and sufentanil 2 micrograms/mL
Study: 30209353
Drug: Curcumin +
Normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin + Fish Oil (1.2 g)
Study: 30209353
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (1.2 g)
Study: 24373369
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy
Study: 25122648
Drug: 1.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g/d of EPA+DHA from fish oil (FO)
Study: 25122648
Drug: 0.9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/d of EPA+DHA from fish oil (FO)
Study: 21531577
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil treatment
Study: 12062463
Drug: Minimal methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal methadone treatment with daily INH DOPT (n=35)
Study: 12062463
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care referral to TB clinic for monthly INH supplies without DOPT and without methadone treatment (n=39)
Study: 9058223
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride 0.15 mg/kg
Study: 8533541
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride 0.19 mg/kg
Study: 8533541
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (all doses)
Study: 2170852
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BC-PS
Study: 2170852
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg BC-PS
Study: 27192505
Drug: Paper patch
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper patch technique
Study: 1099449
Drug: Oral delta‐9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delta‐9‐tetrahydrocannabinol
Study: 30311701
Drug: Elbasvir 50
Normalized name: elbasvir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks
Study: 11826641
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium hyaluronate (HA) 6 mg, injected in the upper compartments of the involved TMJs, three to four injections as one course.
Study: 11826641
Drug: Prednisolone (PS)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PS) 12.5 mg, injected once a week, three to four injections as one course.
Study: 10599905
Drug: Systemic doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic doxycycline at a dosage of 100 mg/day for 14 days
Study: 10599905
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no doxycycline administration)
Study: 28463040
Drug: UD‐DPI (400 μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: UD‐DPI (400 μg, 0.8% lactose blend)
Study: 17251482
Drug: Pentoxifylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (300 mg)
Study: 14698543
Drug: Vinorelbine (V)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (V) 25mg/m2 IV infusion + Gemcitabine (G) 1000 mg/m2 IV infusion on days 1 and 8 of each 21-day cycle
Study: 11008329
Drug: Captopril (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-75 mg/day)
Study: 9562938
Drug: Fosinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10-20 mg/day)
Study: 30870225
Drug: Adjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant capecitabine monotherapy for 8 cycles
Study: 28438924
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (rifampin and isoniazid for 6 months; pyrazinamide and ethambutol for 2 months)
Study: 22013794
Drug: Lipid-reducing red
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-reducing red rice minute powder (LRRMP) 175 mg/pill, 2 pills daily for 6 months
Study: 19079839
Drug: High-soya diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soya diet (two daily servings with 3035mg isoflavones per serving)
Study: 22079088
Drug: Sitaxsentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 100 mg
Study: 22079088
Drug: Sitaxsentan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 50 mg
Study: 11306776
Drug: Heparin (activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (activated partial thromboplastin time 2‐3 times of baseline value)
Study: 7524296
Drug: Amiodarone 100
Normalized name: amiodarone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 100 mg/day
Study: 2655611
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg/d
Study: 2655611
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg/d
Study: 239414
Drug: Ephedrine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (25 mg)
Study: 10589631
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg/mL
Study: 15635515
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg/mL
Study: 30760332
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH vacuum pump
Study: 30760332
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy consisting of Acticoat TM and Mepitel TM
Study: 17504895
Drug: Baseline bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline bone age delay, target height SDS, baseline height SDS, and GH dose
Study: 15354005
Drug: Scopolamine 0.4
Normalized name: scopolamine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.4 mg
Study: 15354005
Drug: Meclizine 25
Normalized name: meclizine 25 MG
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine 25 mg
Study: 9678531
Drug: Evening s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening s.c. GH injections (2 IU)
Study: 9678531
Drug: Morning s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning s.c. GH injections (2 IU)
Study: 2294131
Drug: No GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GH administration
Study: 9678531
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of GH (2000-2000 h)
Study: 5565516
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (stopped or changed)
Study: 5565516
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (remained on the same)
Study: 11140558
Drug: SRP+gel
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP+gel
Study: 12490770
Drug: Moclobemide (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300-600 mg/day)
Study: 3897082
Drug: Ephedrine 50
Normalized name: Ephedrine 50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 50 mg t.i.d.
Study: 29895502
Drug: Live-attenuated Suvaxyn®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated Suvaxyn® CSF Marker vaccine (CP7_E2alf), administered intramuscularly on day 44 of gestation.
Study: 19830558
Drug: Probiotics (Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bacillus subtilis and Streptococcus faecium) for 2 weeks with oral sodium phosphate (NaP)
Study: 19830558
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral sodium phosphate (NaP)
Study: 8708713
Drug: Ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 32 mg
Study: 16766588
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg with dexamethasone
Study: 12869893
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 13-15 mg/kg/d
Study: 31599168
Drug: Group counselling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counselling (4 weekly sessions)
Study: 31520480
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with porous tantalum rod implantation and intra-arterial infusion of peripheral blood stem cells (PBSCs)
Study: 16790655
Drug: Intravenous small-dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous small-dose morphine (4 mg/70 kg)
Study: 9734695
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LoDAC)
Study: 2550700
Drug: CMV‐HIGP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV‐HIGP (1 ml per kilogram of body weight) every two to three weeks initially, with double dose for basic immunisation protection
Study: 22253279
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of glucose syrup 15%
Study: 16309081
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (all methods combined)
Study: 27127
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg Pindolol (Visken)
Study: 25514804
Drug: Afatinib (≤50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (≤50 mg daily, monotherapy)
Study: 23616386
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.p.) and Dermatophagoides farina (D.f.) extract (n = 60)
Study: 22038349
Drug: Doxofylline oral
Normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline oral tablets (0.2 g/time, 2 times a day)
Study: 26211516
Drug: Shakuyakukanzoto (SKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shakuyakukanzoto (SKT) 2.5 g/day
Study: 20100811
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg alagebrium twice daily
Study: 10744202
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide 2% (Trusopt) three times daily for three days
Study: 10744202
Drug: Oral acetozolamide
Normalized name: acetazolamide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetozolamide (Diazomide) 250 mg three times daily for three days
Study: 8774390
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous 1 alpha(OH)D3 treatment for > 300 days
Study: 8774390
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral 1 alpha(OH)D3 treatment for 100 days
Study: 8774390
Drug: Reinstatement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstatement of intermittent intravenous 1 alpha(OH)D3 treatment for another 100 days
Study: 1727741
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg (b.i.d.)
Study: 6653133
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg) plus metoclopramide (5 mg)
Study: 6653133
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg) alone
Study: 2544829
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone
Study: 26350667
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 30 mg b.i.d.
Study: 23870610
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (2.5 mg) after ticagrelor (270 mg single dose, then 180 mg BID for 6 days)
Study: 19775041
Drug: Lactated solution
Normalized name: lactate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated solution (Hartmann's solution; anions: chloride 109 mmol/l, lactate 29 mmol/l)
Study: 19775041
Drug: Chloride-only solution
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride-only solution (Ringer's Injection; anions: chloride 152 mmol/l)
Study: 8163252
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once daily at bedtime
Study: 28749571
Drug: Intravenous L-ornithine
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-ornithine L-aspartate (LOLA), 30g daily for 5 days
Study: 25803546
Drug: Control capsules
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsules
Study: 23593611
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a plus ribavirin therapy (Clinical Trial group)
Study: 23593611
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a plus ribavirin therapy (Cohort group)
Study: 19932589
Drug: ProMECE-CytaBOM infusion
Normalized name: PROMACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProMECE-CytaBOM infusion
Study: 12520631
Drug: Nizatidine CR
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine CR 150 mg bid
Study: 12520631
Drug: Nizatidine CR
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine CR 300 mg daily
Study: 7934692
Drug: Preoperative iliohypogastric
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Study: 7934692
Drug: Postoperative iliohypogastric
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Study: 20146569
Drug: Rotterdam Empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotterdam Empirical Steering Guidelines (RESG) during the second and third treatments
Study: 20146569
Drug: Hyperthermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia treatment planning guided steering (HGS) during the fourth and fifth treatments
Study: 20146569
Drug: Rotterdam Empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotterdam Empirical Steering Guidelines (RESG) during the fourth and fifth treatments
Study: 25809790
Drug: Couple-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based treatment with emphasis on 'we' language
Study: 25809790
Drug: Couple-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based treatment with emphasis on 'you' and 'I' language
Study: 22080174
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg H5N1 haemagglutinin antigen
Study: 22080174
Drug: Cross-reactive antibody
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-reactive antibody response
Study: 22080174
Drug: Persistence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistence of antibodies
Study: 22080174
Drug: Safety of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety of the vaccine